Insulin glargine biosimilar (Wanbang Biochemical)

重组甘精胰岛素生物类似药（万邦医药）

Report date: 2022/09/05 09:51:08

Base Information

Drug NameInsulin glargine biosimilar (Wanbang Biochemical)
Drug Alias Name重组甘精胰岛素生物仿制药（万邦医药）甘精胰岛素生物仿制药（万邦医药）
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2022/08/30
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFosun Wanbang (Jiangsu) Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeA10AE04
Related LinksN/A